Miflonide Breezhaler (Budesonide)

Budesonide binds to glucocorticoid receptors inside airway cells, altering gene expression to suppress inflammatory mediators such as cytokines and chemokines. This reduces eosinophil activity, edema, and mucus production, leading to improved airway caliber and reduced hyper‑responsiveness.

The prescribed dose of Miflonide Breezhaler is determined by the treating physician based on the patient’s age, disease severity, and response to therapy. Dosing instructions are provided on the prescription label and should be followed exactly as directed.

Safety data for budesonide inhalation during pregnancy are limited, and the product should only be used if the potential benefit justifies any potential risk to the fetus. Breastfeeding mothers should consult their healthcare provider, as small amounts may be excreted in milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Miflonide Breezhaler delivers budesonide via the Breezhaler device, offering consistent dose delivery and a low systemic exposure profile compared with some older inhaled steroids. Its particle size and formulation are designed for deep lung penetration, making it comparable to other high‑efficacy inhaled corticosteroids such as fluticasone.

Store Miflonide Breezhaler at room temperature, below 25 °C, in the original packaging. Keep the device away from moisture and direct sunlight, and ensure the inhaler is closed when not in use to maintain powder integrity.

The patient inhales the powder through the Breezhaler device by placing the mouthpiece in the mouth, sealing lips around it, and taking a deep, steady breath. After inhalation, the patient should hold their breath for a few seconds to allow optimal drug deposition.

Serious risks include paradoxical bronchospasm, adrenal suppression with prolonged high‑dose use, and rare cases of pneumonia, especially in patients with COPD. Patients should seek immediate medical attention if they experience sudden worsening of breathing or signs of infection.

Miflonide Breezhaler is contraindicated in individuals with a known hypersensitivity to budesonide or any component of the formulation. It should also be avoided in patients with untreated active infections of the respiratory tract until the infection is resolved.